Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kineret Gets Rheumatologist Promotions From 35-Rep NPS Force

Executive Summary

NPS will promote Amgen's rheumatoid arthritis agent Kineret to rheumatologists with a 35 member specialty sales force

You may also be interested in...



Amgen keeps Kineret

Amgen will keep IL-1 inhibitor Kineret (anakinra) for treatment of rheumatoid arthritis under a proposed consent agreement between Amgen and Federal Trade Commission that would allow the company's proposed acquisition of Immunex to proceed. FTC's July 12 announcement of the agreement notes that Kineret has had sales in excess of $2.4 mil. since its launch in November. The agreement would require the company to divest one of Immunex' marketed products, the neutrophil regeneration factor Leukine (sargramostim) (1"The Pink Sheet" Dec. 24, 2001, p. 16)...

Leukine Is Divestment Candidate In Amgen/Immunex Deal

Immunex' Leukine is available for licensing as part of Amgen's acquisition of the biotech company

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS044508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel